Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)

Transfusion

Volumn 59, Issue 1, 2019, Pages 217-225

  Karafin, Matthew S ^a   Tan, Sylvia ^b   Tormey, Christopher A ^c,d   Spencer, Bryan R ^c,e   Hauser, Ronald G ^c,d   Norris, Philip J ^f,g   Roubinian, Nareg H ^f,g   Wu, Yanyun ^c,h   Triulzi, Darrell J ⁱ   Kleinman, Steve ^j   Gottschall, Jerome L ^a   Hendrickson, Jeanne E ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RTI INTERNATIONAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Digestive Disease Section   (United States)

^e AMERICAN RED CROSS   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^h BloodWorks Northwest   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY; RHESUS D ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD GROUP DUFFY SYSTEM; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENDER; HUMAN; MALE; MIDDLE AGED; PARITY; PREGNANCY; PREVALENCE; RISK FACTOR; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ERYTHROCYTE; IMMUNOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; STATISTICAL MODEL;

ADOLESCENT; ADULT; BLOOD DONORS; ERYTHROCYTES; FEMALE; HUMANS; ISOANTIBODIES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREGNANCY; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 85056449126     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15004     Document Type: Article

References (30)

1. Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014;28:137-44
2. FDA. US Department of Health and Human Services. Fatalities reported to the FDA following blood collection; Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability, accessed July 1, 2018
3. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505-12
4. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132-9
5. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev 2016;30:159-64
6. Bollason G, Hjartardottir H, Jonsson T, et al. Red blood cell alloimmunization in pregnancy during the years 1996–2015 in Iceland: a nation-wide population study. Transfusion 2017;57:2578-85
7. AABB. Standards for blood banks and transfusion services. 31st ed. Bethesda, MD: AABB; 2018
8. 21 Code of federal regulations, 606.151. In: Department of health and human services, US food and drug administration. 2018
9. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009;49:1825-35
10. Dunbar NM, Yazer MH, Bravo MD, et al. An association between ABO group and HLA antibody detection. Transfusion 2017;57:313-8
11. Garcia MA, Bautista L, Palomino F. Should blood donors be routinely screened for irregular antibodies? Immunohematology 2012;28:60-6
12. Myhre BA, Greenwalt TJ, Gajewski M. Incidence of irregular antibodies occurring in healthy donor sera. Transfusion 1965;5:350-4
13. Plumbley JA, Shelton JB Jr, Bowlus IN, et al. The incidence of unexpected antibodies in blood products collected at a military donor center. Mil Med 1999;164:705-6
14. Karafin MS, Westlake M, Hauser RG, et al. Risk factors for red blood cell alloimmunization in the recipient epidemiology and donor evaluation study (REDS-III) database. Br J Haematol 2018;181:672-81
15. Pahuja S, Kushwaha S, Sethi N, et al. Screening of blood donors for erythrocyte alloantibodies. Hematology 2012;17:302-5
16. Winters JL, Pineda AA, Gorden LD, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 2001;41:1413-20
17. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008;48:2069-76
18. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996;71:216-20
19. Miller ST, Kim HY, Weiner DL, et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013;53:704-9
20. Zalpuri S, Zwaginga JJ, le Cessie S, et al. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012;102:144-9
21. Verduin EP, Brand A, Middelburg RA, et al. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion 2015;55:1478-85
22. Al-Mousawi MM, Al-Allawi NA, Alnaqshabandi R. Predictors of red cell alloimmunization in kurdish multi transfused patients with hemoglobinopathies in Iraq. Hemoglobin 2015;39:423-6
23. Contreras M, de Silva M, Teesdale P, et al. The effect of naturally occurring Rh antibodies on the survival of serologically incompatible red cells. Br J Haematol 1987;65:475-8
24. Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev 2012;26:342-53 353.e1–e5
25. Ameen R, Al-Eyaadi O, Al-Shemmari S, et al. Frequency of red blood cell alloantibody in Kuwaiti population. Med Princ Pract 2005;14:230-4
26. Giblett ER. Blood group alloantibodies: an assessment of some laboratory practices. Transfusion 1977;17:299-308
27. Delaney M, Wikman A, van de Watering L, et al. Blood group antigen matching influence on gestational outcomes (AMIGO) study. Transfusion 2017;57:525-32
28. Verduin EP, Brand A, van de Watering LM, et al. Factors associated with persistence of red blood cell antibodies in woman after pregnancies complicated by fetal alloimmune haemolytic disease treated with intrauterine transfusions. Br J Haematol 2015;168:443-51
29. Mohn JF, Lambert RM, Bowman HS, et al. Experimental transfusion of donor plasma containing blood-group antibodies into incompatible normal human recipients. I. Absence of destruction of red-Kell and anti-M. Br J Haematol 1961;7:112-29
30. Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion 2016;56:2662-7